Tianjin TEDA Biomedical Engineering Company Limited logo

Tianjin TEDA Biomedical Engineering Company Limited

8189.HK

HKSEBasic MaterialsAgricultural Inputs

Latest quote

HK$0.26

−HK$0.01 · -3.70%

Aug 24, 2:39 PM HKTData delayed

8189.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compound fertilizer products throughout the PRC. Its operations are organized into two main divisions: Biological Compound Fertilizers and Elderly and Health Care Services. The company's agricultural offerings encompass active fertilizers and various tailored blends of nitrogen, phosphorus, and potassium, specifically formulated to promote balanced growth for a range of crops including grains, fruits, and vegetables. Beyond agriculture, Tianjin TEDA Biomedical provides integrated care for the elderly and comprehensive health services. This includes leasing essential equipment for seniors and offering specialized consulting, advisory, and assessment solutions. Furthermore, the company develops and licenses electroencephalography (EEG) diagnosis detection services, utilizing its expertise in EEG technology for diagnostic applications. Its extensive activities also cover the research, development, production, and practical application of biomedical science and technology projects, alongside regional soil resource conditioning and remediation, and the provision of soil environmental quality standards research services.

Industry
Agricultural Inputs
Sector
Basic Materials
Headquarters
CN
CEO
Li Sun
Listed since
Jun 18, 2002
Employees
273

Market position

Day range

Current HK$0.26

52-week range

Current HK$0.26

Open
HK$0.255
Previous close
HK$0.27
Volume
365K
0.53× average
Average volume
685.4K
Average daily volume
Market cap
554.81M HKD
Beta
-0.44
Market reference 1
50-day average
HK$0.1618
+60.65% above average
200-day average
HK$0.2597
+0.11% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
650.28M CNY
P/E (TTM)
-3.55×
P/B (TTM)
38.01×
P/S (TTM)
0.71×
EV / EBITDA
-45.41×
Earnings yield
-15.53%
Free cash flow yield
-11.03%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
5.22%
Operating margin
-7.18%
Net margin
-19.75%
Return on equity
-723.42%
Return on assets
-33.39%
Return on invested capital
-20.64%

Financial health

Debt / equity
8.98×
Current ratio
0.75×
Altman Z-score
0.02
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends12%1%-9%-20%Gross margin, FY2021: 9.57%Gross margin, FY2022: 3.67%Gross margin, FY2023: 5.37%Gross margin, FY2024: 4.40%Gross margin, FY2025: 6.82%Operating margin, FY2021: -3.86%Operating margin, FY2022: -6.05%Operating margin, FY2023: -2.47%Operating margin, FY2024: -7.36%Operating margin, FY2025: -4.63%Net margin, FY2021: -8.87%Net margin, FY2022: -6.80%Net margin, FY2023: -5.07%Net margin, FY2024: -7.21%Net margin, FY2025: -17.37%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 9.57%. Gross margin FY2022 3.67%. Gross margin FY2023 5.37%. Gross margin FY2024 4.40%. Gross margin FY2025 6.82%. Operating margin FY2021 -3.86%. Operating margin FY2022 -6.05%. Operating margin FY2023 -2.47%. Operating margin FY2024 -7.36%. Operating margin FY2025 -4.63%. Net margin FY2021 -8.87%. Net margin FY2022 -6.80%. Net margin FY2023 -5.07%. Net margin FY2024 -7.21%. Net margin FY2025 -17.37%.

Income trends

Revenue

509.43M CNY+32.15%

Operating income

−23.57M CNY+16.97%

Net income

−88.47M CNY-218.21%
Income trends across reported periods569.22M CNY330.06M CNY90.9M CNY−148.26M CNYRevenue, FY2021: 476.38M CNYRevenue, FY2022: 403.73M CNYRevenue, FY2023: 398M CNYRevenue, FY2024: 385.48M CNYRevenue, FY2025: 509.43M CNYOperating income, FY2021: −18.39M CNYOperating income, FY2022: −24.41M CNYOperating income, FY2023: −9.83M CNYOperating income, FY2024: −28.38M CNYOperating income, FY2025: −23.57M CNYNet income, FY2021: −42.26M CNYNet income, FY2022: −27.45M CNYNet income, FY2023: −20.16M CNYNet income, FY2024: −27.8M CNYNet income, FY2025: −88.47M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 476.38M CNY. Revenue FY2022 403.73M CNY. Revenue FY2023 398M CNY. Revenue FY2024 385.48M CNY. Revenue FY2025 509.43M CNY. Operating income FY2021 −18.39M CNY. Operating income FY2022 −24.41M CNY. Operating income FY2023 −9.83M CNY. Operating income FY2024 −28.38M CNY. Operating income FY2025 −23.57M CNY. Net income FY2021 −42.26M CNY. Net income FY2022 −27.45M CNY. Net income FY2023 −20.16M CNY. Net income FY2024 −27.8M CNY. Net income FY2025 −88.47M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue509.43M CNY385.48M CNY398M CNY403.73M CNY476.38M CNY
Cost of goods sold474.68M CNY368.51M CNY376.63M CNY433.28M CNY430.78M CNY
Gross profit34.75M CNY16.97M CNY21.37M CNY14.82M CNY45.6M CNY
Research and development4.03M CNY1.1M CNY1.32M CNY1.14M CNY3.5M CNY
Selling, general, and administrative32.22M CNY34.26M CNY29.91M CNY37.49M CNY48.76M CNY
Operating expenses58.32M CNY45.35M CNY31.2M CNY38.51M CNY63.99M CNY
Interest income75.59K CNY47.97K CNY249.97K CNY762.8K CNY430.83K CNY
Interest expense3.69M CNY4.58M CNY5.17M CNY6.4M CNY5.47M CNY
Depreciation and amortization9.25M CNY8.2M CNY11.63M CNY15.39M CNY9.51M CNY
Operating income−23.57M CNY−28.38M CNY−9.83M CNY−24.41M CNY−18.39M CNY
Net income−88.47M CNY−27.8M CNY−20.16M CNY−27.45M CNY−42.26M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0-0.02-0.03-0.04Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q3 '25
Q1 2023, reported Mar 30, 2023: actual -0.003, estimate —, surprise —, Comparison unavailable. Q2 2023, reported May 10, 2023: actual -0.005, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 10, 2023: actual -0.003, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 9, 2023: actual -0.003, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual -0.002, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 26, 2024: actual -0.001, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual -0.001, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 6, 2025: actual -0.002, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates171.4M144.95M118.5M92.06MQ1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q3 '25
Q1 2023, reported Mar 30, 2023: actual 164.8M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported May 10, 2023: actual 98.65M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 10, 2023: actual 107.6M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 9, 2023: actual 127.97M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual 102.67M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 26, 2024: actual 114.45M HKD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 30, 2024: actual 113.6M HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 6, 2025: actual 123.86M HKD, estimate —, surprise —, Comparison unavailable.

8189.HK peers

Continue in GoAI

Research 8189.HK

research.disclaimer